Health & Biotech
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance.
The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
ASX Large Caps: Coles takes lead as iron ore miners struggle; Bitcoin nears US$56k
Health & Biotech
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns
Health & Biotech
ASX Health Stocks: Amplia gets FDA green light to commence trial; Recce study meets all primary endpoints
Health & Biotech
ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1
Health & Biotech
ASX Health Stocks: Chimeric jumps 35pc as cell therapy drug shows pre-clinical efficacy
Health & Biotech
ASX Health Stocks: Recce moves forward in Phase 1/2 study; EMV unveils Gen 2 helmet scanner for ambulance
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Health Stocks: Bod Science surges 20pc on cannabis trial results; Recce gets Vietnam trade mark
Health & Biotech
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
News
Top 10 at 10: James Hardie delivers super strong quarter; Auris digs up more gold
News
In Case You Missed It: Gold, biotech and some gas
Health & Biotech
ASX Health Stocks: Recce Pharma and Impedimed surge 15pc after positive announcements
News
ASX Small Caps Lunch Wrap: What sparked the tragedy of America’s Biggest Barbecue this week?
News
Market Highlights: Aussie becomes first to sue ChatGPT for defamation, and 5 ASX small caps to watch today
Health & Biotech
ASX Health Stocks: HeraMED is traveling smoothly in the US; Recce names Adelaide firm to run Phase1/2 trial
Health & Biotech
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
News